Fundraisings and IPOs

Date: 2017-01-20

Type of information: Private placement

Company: Stemline Therapeutics (USA - NY)

Investors:

Amount: $45 million

Funding type: private placement

Planned used:

Stemline intends to use the net proceeds from the public offering for

• clinical, regulatory, manufacturing and, if and when approved, potential commercial activities of SL-401;
•  clinical development of SL-801, an oral, small molecule inhibitor of Exportin 1 (XPO1), a clinically validated oncology target overexpressed by many solid and hematologic cancers, and SL-701, a glioma-associated antigen vaccine;
• research and development activities; and
• other general corporate purposes.

Others:

* On January 20, 2017, Stemline Therapeutics announced the pricing of an underwritten public offering of 4.5 million shares of its common stock at a price of $10.00 per share, with expected gross proceeds to Stemline of $45 million. In addition, Stemline has granted the underwriters a 30-day option to purchase up to 675,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on January 25, 2017, subject to customary closing conditions.
Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Ladenburg Thalmann & Co. Inc. and H.C. Wainwright & Co. are acting as co-lead managers and Roth Capital Partners, Joseph Gunnar & Co., LLC and Aegis Capital Corp. are acting as co-managers for the offering.

Therapeutic area: Cancer - Oncology

Is general: Yes